| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Dianthus Therapeutics Inc. | Claseprubart - (MaGic) | Generalized Myasthenia Gravis (gMG) | Phase 2 | Data Released | Oral | Neurology |
| Dianthus Therapeutics Inc. | Claseprubart (DNTH103) - (MaGic) | Myasthenia Gravis (gMG) | Phase 2 | Data Released | Subcutaneous | Neurology |
| Dianthus Therapeutics Inc. | DNTH103 - (MoMeNtum) | Multifocal Motor Neuropathy (MMN) | Phase 2 | Ongoing | Subcutaneous | Neurology |
| Disc Medicine Inc. | Bitopertin - (APOLLO) | Erythropoietic Protoporphyria (EPP) | Phase 3 | Ongoing | Oral | Genetic Disorder |
| Disc Medicine Inc. | Bitopertin - (BEACON) | Erythropoietic Protoporphyria (EPP) | NDA Filing | Data Released | Oral | Genetic Disorder |
| Disc Medicine Inc. | Bitopertin - (BEACON) | Erythropoietic Protoporphyria (EPP) | NDA Filing | Data Released | Oral | Genetic Disorder |
| Disc Medicine Inc. | Bitopertin - (HELIOS) | Erythropoietic Protoporphyria | Phase 2 | Data Released | Oral | Genetic Disorder |
| Disc Medicine Inc. | DISC-3405 | Inflammatory bowel disease | Phase 2 | Trial Planned | Oral | Gastroenterology |